Lv1
20 积分 2025-07-22 加入
Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
9个月前
已完结
Postmarketing safety of anaplastic lymphoma kinase (ALK) inhibitors: an analysis of the FDA Adverse Event Reporting System (FAERS)
9个月前
已完结
Characterization and corroboration of safety signals identified from the US Food and Drug Administration Adverse Event Reporting System, 2008-19: cross sectional study
9个月前
已完结
<p>The safety and serious adverse events of approved ALK inhibitors in malignancies: a meta-analysis</p>
9个月前
已关闭
Hepatic adverse events associated with anaplastic lymphoma kinase tyrosine kinase inhibitors: a disproportionality analysis based on FAERS Database and analysis of drug-gene interaction network
9个月前
已完结
Meta-analysis of overall incidence and risk of ALK inhibitors-induced liver toxicities in advanced non-small-cell lung cancer
9个月前
已完结
皖公网安备34019202002308
